LOS ANGELES, March 3, 2014 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that Andrew Gengos, Chief
Executive Officer of ImmunoCellular, will present a corporate
overview and business update at the 26th Annual ROTH
Conference on Tuesday, March 11, 2014
at 5:00 pm PT, at the Ritz-Carlton
Hotel, Laguna Niguel,
CA.
To access the live audio webcast of the ROTH presentation,
please log on through a link located in the Investors section of
ImmunoCellular's website at www.imuc.com, under the Events &
Presentations tab. A replay of the webcast will be available one
hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular has concluded a phase II trial of its
lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular's pipeline also includes ICT-121, a dendritic cell
vaccine targeting CD133, and ICT-140, a dendritic cell vaccine
targeting ovarian cancer antigens and cancer stem cells. To learn
more about ImmunoCellular, please visit www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green
Investor Relations
415.348.0010
jane@jmgcomm.com
Photo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
SOURCE ImmunoCellular Therapeutics, Ltd.